Bajaj Healthcare receives exclusive rights for manufacturing, distribution & sales of finished formulation of Magnesium L Threonate

Bajaj Healthcare Limited has received exclusive rights for manufacturing, distribution & sales of the finished formulation of the Magnesium L Threonate (Magtein) in India from the rights holder, Threotech LLC.

Threotech LLC has granted Bajaj Healthcare Limited the licensing rights to manufacture finished formulation of Magnesium L Threonate (Magtein) along with the rights to enter into marketing collaborations with leading branded pharmaceutical firms for the Indian market.

Bajaj Healthcare Limited will therefore have the rights to manufacture/ market/distribute/co-market in the Indian market for Magnesium L Threonate (Magtein).

The company is already supplying the API Magnesium L Threonate (Magtein), to the patent holder in the United States of America.

The API is supplied by Bajaj Healthcare Ltd. for the brand Magtein in the United States of America as an exclusive arrangement. The brand Magtein by Threotech LLC has a sales value of approximately US $438 million.

Speaking at the occasion Anil Jain, Managing Director, Bajaj Healthcare Limited said, “Our collaboration with Threotech LLC has taken an exciting step forward after receiving licensing rights for manufacturing, marketing and selling their innovative product, Magtein, in India. With our strong domestic presence and proven manufacturing & distribution expertise, we are well-positioned to unlock the product’s full potential in the Indian market. This development reaffirms our position as a trusted partner to our international clients and underscores our ability to seamlessly integrate manufacturing & quality excellence with strategic market outreach.”